We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Metabolic Effects of Paricalcitol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01003275
Recruitment Status : Completed
First Posted : October 28, 2009
Results First Posted : September 27, 2013
Last Update Posted : April 28, 2014
Information provided by (Responsible Party):

October 26, 2009
October 28, 2009
June 18, 2013
September 27, 2013
April 28, 2014
October 2009
November 2011   (Final data collection date for primary outcome measure)
Glucose Area Under the Curve (AUC) [ Time Frame: 8 weeks ]
Glucose AUC during a 2-hour oral glucose tolerance test
Change in glucose area under curve (AUC) following an oral glucose tolerance test [ Time Frame: 8 weeks ]
Complete list of historical versions of study NCT01003275 on ClinicalTrials.gov Archive Site
Not Provided
  • Ratio of incremental AUC for C-peptide to incremental AUC for glucose [ Time Frame: 8 weeks ]
  • Mean of fasting insulin measurements [ Time Frame: 8 weeks ]
  • Cytokine expression profiles of T-cells and monocytes [ Time Frame: 8 weeks ]
  • Serum cytokine profile [ Time Frame: 8 weeks ]
  • Urine cytokine profile [ Time Frame: 8 weeks ]
  • Urine F2-isoprostane excretion [ Time Frame: 8 weeks ]
Not Provided
Not Provided
Metabolic Effects of Paricalcitol
Effects of Oral Paricalcitol on Glucose Tolerance, Immune Cell Function, and Oxidative Stress in Stage 3-4 Chronic Kidney Disease
The purpose of this study is to determine if treatment with paricalcitol, an active form of vitamin D, has beneficial effects on metabolic abnormalities in people with stage 3-4 Chronic Kidney Disease (CKD).

Persons with chronic kidney disease (CKD) are at markedly increased risk of death, particularly from cardiovascular disease (CVD). A number of metabolic abnormalities may contribute to adverse health outcomes in CKD, including glucose intolerance, altered immune cell function, and oxidative stress. Each of these metabolic stressors is a known complication of CKD. Since these metabolic abnormalities are also known to contribute to the pathogenesis of cardiovascular disease, they are important potential therapeutic targets in CKD.

This study will test whether oral paricalcitol, an active form of vitamin D, will improve glucose tolerance, immune cell function, and reduce oxidative stress in people with stage 3-4 chronic kidney disease.

Phase 2
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Chronic Kidney Disease
  • Drug: Paricalcitol
    Two 1 mcg soft gels by mouth daily for 8 weeks
    Other Name: Zemplar
  • Drug: Placebo
    Two soft gels by mouth daily for 8 weeks
  • Active Comparator: Paricalcitol followed by placebo
    Participants will receive paricalcitol for 8 weeks, then an 8-week wash-out, then placebo for 8 weeks.
    • Drug: Paricalcitol
    • Drug: Placebo
  • Active Comparator: Placebo followed by paricalcitol
    Participants will receive placebo for 8 weeks, then an 8-week wash-out, then paricalcitol for 8 weeks.
    • Drug: Paricalcitol
    • Drug: Placebo
de Boer IH, Sachs M, Hoofnagle AN, Utzschneider KM, Kahn SE, Kestenbaum B, Himmelfarb J. Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease. Kidney Int. 2013 Feb;83(2):323-30. doi: 10.1038/ki.2012.311. Epub 2012 Aug 22.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
November 2011
November 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Estimated glomerular filtration rate of 15-59 mL/min/1.73m2
  • Fasting glucose 100-125 mg/dL
  • 18 years and older

Exclusion Criteria:

  • Diagnosed with diabetes mellitus
  • Use of diabetes medications (insulin or oral hypoglycemics)
  • Prior dialysis or transplantation
  • Planning to leave the area within 6 months
  • Participation in another clinical trial within 30 days
  • Treatment with paricalcitol, calcitriol, or corticosteroids in the preceding 8 weeks
  • Serum calcium more than 10.2 mg/dL
  • Pregnancy or breast-feeding
  • Change in dose (within 8 weeks) of Fibrates, Niacin, ACE inhibitors, Angiotensin receptor blockers, Thiazide diuretics, Beta-blockers, Cholecalciferol or Ergocalciferol
  • Incontinent of urine
  • Cancer (other than skin cancer) within 5 years
  • Tuberculosis
  • Sarcoidosis
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Ian deBoer, University of Washington
University of Washington
Principal Investigator: Ian H de Boer, MD, MS University of Washington
University of Washington
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP